Entero Healthcare Solutions Ltd (ENTERO) is currently trading at 1,971.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Entero Healthcare Solutions is an organized, pan-India distributor of pharmaceutical and healthcare products, supplying retail pharmacies, hospitals, clinics, and government or institutional customers. It combines a broad manufacturer network, extensive warehouse infrastructure, technology-enabled distribution, and expanding MedTech capabilities to improve healthcare-product access across India. Consolidated revenue increased 32.9% year-on-year to INR2,087 crore in Q2 FY27, while EBITDA grew 78% and profit after tax rose 66%. Growth was supported by organic expansion, acquisition calendarisation, procurement efficiencies, a higher MedTech contribution, and the deliberate exit from selected low-margin accounts. Entero Healthcare Solutions served more than 92,200 retail customers and 2,900 hospitals across approximately 500 districts and over 20 states and union territories during the first half. Its network distributed more than 90,400 SKUs sourced from over 3,200 manufacturers, creating a meaningful two-sided ecosystem moat. MedTech contributed approximately 15% or around INR600 crore of first-half revenue and is expected to exceed the earlier INR1,000 crore full-year aspiration. Management views MedTech as a major organic growth opportunity because additional categories, manufacturer partnerships, demand-generation services, and value-added distribution can improve the portfolio mix. Operating cash flow was negative INR46.5 crore in the first half because of a temporary INR55 crore delay involving Maharashtra government-contract collections. Management said the funds were received in November and reiterated the full-year objective of converting 50% of EBITDA into operating cash flow.

Over the past 52 weeks, Entero Healthcare Solutions Ltd has traded between a low of ₹944.00 and a high of ₹2,132.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Entero Healthcare Solutions Ltd has a market capitalization of approximately 8,733.29. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Entero Healthcare Solutions Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 45.53 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 8,733.29 Cr, Entero Healthcare Solutions Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Entero Healthcare Solutions Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Entero Healthcare Solutions Ltd is 45.53. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Entero said the 137 molecules currently notified by NPPA account for 2% of its portfolio sales. Management used that figure to explain why it does not currently expect a material company-wide effect.

Entero said MedTech accounted for more than 15% of total revenue in H1 FY27. The company did not disclose the segment's exact rupee revenue, so its sales cannot be calculated precisely from the 15%-plus statement.

Entero said it is generally more interested in product expansion than geographic expansion. It is evaluating transactions that add product categories or portfolios, as well as opportunities in geographies where its presence is limited.

Entero’s stated FY27 guidance is approximately 23% consolidated revenue growth excluding new acquisitions, a 5% EBITDA margin, and 50% EBITDA-to-operating-cash-flow conversion. Management said on November 5, 2026, that it expects to do better than those targets without issuing revised numerical guidance.